Allergan selloff today a buying opportunity, says Leerink

Leerink analyst Marc Goodman views today’s 7% selloff in shares of Allergan based on the breast implant news as a buying opportunity. While the suspension of sales is an incremental negative and likely to bring down consensus numbers, 2019 should bring increasingly visibility for Botox durability and the company’s the pipeline, Goodman tells investors in a research note. He keeps an Outperform rating on Allergan, which is down $11.01 to $135.82 in afternoon trading.
https://thefly.com/landingPageNews.php?id=2839433